Bacterial otitis media: Current vaccine development strategies

Immunology and Cell Biology

Volumn 81, Issue 1, 2003, Pages 46-51

  Cripps, Allan W ^a   Kyd, Jennelle ^a  

^a UNIVERSITY OF CANBERRA   (Australia)

Author keywords

Bacteria; Immunity; Inflammation; Otitis media; Vaccine

Indexed keywords

ANTIGEN; ANTIINFECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CHILDHOOD; DRUG EFFICACY; DRUG FORMULATION; HAEMOPHILUS INFLUENZAE; HEARING LOSS; IMMUNE RESPONSE; INFLAMMATION; MORAXELLA CATARRHALIS; MORBIDITY; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; REVIEW; RODENT; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANIMALS; BACTERIAL INFECTIONS; EAR, MIDDLE; OTITIS MEDIA; RATS; VACCINES;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); ENTEROVIRUS; HAEMOPHILUS INFLUENZAE; INFLUENZA VIRUS; MORAXELLA CATARRHALIS; RESPIRATORY SYNCYTIAL VIRUS; RODENTIA; STREPTOCOCCUS PNEUMONIAE; SYNCYTIAL VIRUS;

EID: 0037329699     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0818-9641.2002.01141.x     Document Type: Review

References (56)

1. Bluestone CD, Klein JO. Otitis media with effusion, atelectasis and eustachian tube dysfunction. In: Bluestone CD, Stool SE, (eds). Pediatric Otolaryngology Philadelphia: WB Saunders, 1983; 356.
2. Curotta JH. Managing Acute Otitis Media. Mod. Med. Aust. 1996; 56-63.
3. Rosenfeld JA, Clarity G. Acute otitis media in children. Prim. Care 1996; 23: 677-86.
4. Bluestone CD. Modern management of otitis media. Pediatr. Clin. North Am. 1996; 36: 1371-87.
5. Teele DJ, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective cohort study. J. Infect. Dis. 1989; 160: 83-94.
6. Klein JO. Otitis media. Clin. Infect. Dis. 1994; 19: 823-33.
7. Alsarraf R, Hung CJ, Perkins J, Crowley C, Alsarraf NW, Gates GA. Measuring the indirect and direct costs of acute otitis media. J Arch. Otaryngol. Head Neck Surg. 1999; 125: 12-18.
8. Elden L, Coyte P. Socio-economic impact of otitis media in North America. J. Otolaryngol. 1998; 26: 9-16.
9. Klein JO. The burden of otitis media. Vaccine 2000; 19: S2-S8.
10. Stool S, Field M. The impact of otitis media. Pediatr. Infect. Dis. J. 1989; 8: S11-S4.
11. Dugdale AE, Canty A, Lewis AN, Lovell S. The natural history of chronic middle ear disease in Australian Aboriginals: a cross-sectional study. Med. J. Aust. 1978; 1: 6-8.
12. Berman S. Otitis media in developing countries. Pediatr. 1995; 96: 126-31.
13. Arola M, Ziegler T, Ruuskanen O. Respiratory virus infection as a cause of prolonged symptoms in acute otitis media. J. Pediatr. 1990; 116: 697-701.
14. Chonmaitree T, Owen MJ, Howie VM. Respiratory viruses interfere with bacteriologic response to antibiotic in children with acute otitis media. J. Infect. Dis. 1990; 162: 546-9.
15. Giebink GS. The microbiology of otitis media. Pediatr. Infect. Dis. J. 1989; 8: S18-20.
16. Post JC, Preston RA, Aul M et al. Molecular analysis of bacterial pathogens in otitis media with effusion. JAMA 1995; 273: 1598-604.
17. Matar GM, Sidani N, Fayad M, Hadi U. Two-step PCR-based assay for identification of bacterial etiology of otitis media with effusion in infected Lebanese children. J. Clin. Microbiol. 1998; 36: 1185-8.
18. Ruuskanen O, Arola M, Heikkinen T, Ziegler T. Viruses in acute otitis media: increasing evidence for clinical significance. Pediatr. Infect. Dis. J. 1991; 10: 425-7.
19. Pitkaranta A, Virolainen A, Jero J, Arruda E, Hayden FG. Detection of rhinovirus, respiratory syncytial virus and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics 1998; 102: 291-5.
20. Bakaletz LO. Otitis Media. In: Brogden KA, Guthmiller JM, eds. Polymicrobial Diseases. Washington: ASM Press, 2002; 259-98.
21. Faden H, Stanievich J, Brodsky L, Bernstein J, Ogra PL. Changes in nasopharyngeal flora during otitis media of childhood. Pediatr. Infect. Dis. J. 1990; 9: 623-6.
22. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N. Engl. J. Med. 1999; 340: 260-4.
23. Harabuchi Y, Faden H, Yamanaka N, Duffy L, Wolf J, Krystofik D. Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media. J. Infect. Dis. 1994; 170: 862-6.
24. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr. Infect. Dis. J. 1997; 16: 1065-8.
25. Barnett ED, Klein JO. The problem of resistant bacteria for the management of acute otitis media. Pediatr. Clin. North Am. 1995; 42: 509-17.
26. Sarkkinen H, Ruuskanen O, Meurman O, Pukakka H, Virolainen E, Eskola J. Identification of respiratory virus antigens in middle ear fluids of children with acute otitis media. J. Infect. Dis. 1985; 151: 444-8.
27. 197- conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect. Immun. 1997; 65: 242-7.
28. de Velasco EO, Merkus D, Anderton S et al. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines. Infect. Immun. 1995; 63: 961-8.
29. Nurkka A, Ahman H, Yaich M, Eskola J, Kayhty H. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine 2001; 20: 194-201.
30. Sato K. Experimental otitis media induced by nonviable Moraxella catarrhalis in the guinea pig model. Auris Nasus Larynx 1997; 24: 233-8.
31. Doyle WJ. Animal models of otitis media: other pathogens. Pediatr. Infect. Dis. J. 1989; 8: S45-S7.
32. Gu XX, Chen J, Barenkamp SJ et al. Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect. Immun. 1998; 66: 1981-7.
33. Suzuki K, Bakaletz LO. Synergistic effect of adenovirus type 1 and nontypeable Haemophilus influenzae in a chinchilla model of experimental otitis media. Infect. Immun. 1994; 62: 1710-18.
34. Prellner K, Hermansson A, White P, Melhus A, Briles D. Immunization and protection in pneumococcal otitis media studied in a rat model. Microbial. Drug Resist. 1999; 5: 73-82.
35. van der Ven LTM, van der Dobbelsteen GPJM, Nagarajah B et al. A new rat model of otitis media caused by Streptococcus pneumoniae conditions and application in immunization protocols. Infect. Immun. 1999; 67: 6098-103.
36. Westman E, Melhus A, Hellstrom S, Hermansson A. Moraxella catarrhalis-induced purulent otitis media in the rat middle ear. Structure, protection, and serum antibodies. APMIS 1999; 107: 737-46.
37. Moore R, Lidbury BA, Cripps AW, Kyd JM. Viral co-infection does not reduce the efficacy of vaccination against non-typeable Haemophilus influenzae middle ear infection in a rat model. J. Otorhinolaryngol. Relat. Spec. 2001; 63: 96-101.
38. Kyd JM, Cripps AW. Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: An overview. Vaccine 1999; 17: 1775-81.
39. Kyd JM, Cripps AW. Nontypeable Haemophilus influenzae: Challenges in developing a vaccine. J. Biotechnol. 1999; 73: 103-8.
40. Kyd J, Cripps A. Identifying vaccine antigens and assessing delivery systems for the prevention of bacterial infections. J. Biotechnol. 2000; 83: 85-90.
41. Akkoyunlu M, Melhus A, Capiau C, van Opstal O, Forsgren A. The acylated form of protein D of Haemophilus influenzae is more immunogenic than the nonacylated form and elicits an adjuvant effect when it is used as a carrier conjugated to polyribosyl ribitol phosphate. Infect. Immun. 1997; 65: 5010-16.
42. Poolman JT, Bukaletz L, Cripps A, Denoel PA, Forsgren A, Kyd J, Lobet Y. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine 2000; 19: Suppl 1: S108-15.
43. Bakaletz LO, Kennedy B-J, Novotny LA, Duquesne G, Cohen J, Lobet Y. Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium infection. Infect. Immun. 1999; 67: 2746-62.
44. Rijneveld AW, Florquin S, Branger J, Speelman P, van Deventer SJ, van der Poll T. TNF-alpha compensates for the impaired host defence of IL-1 receptor-deficient mice during pneumococcal pneumonia. J. Immunol. 2001; 167: 5240-6.
45. Rijneveld AW, Lauw FN, Schultz MJ et al. The role of interferon-gamma in murine pneumococcal pneumonia. J. Infect. Dis. 2002; 185: 91-7.
46. Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 1997; 65: 257-60.
47. Tsao N, Chang WW, Liu CC, Lei HY. Development of hematogenous pneumococcal meningitis in adult mice. The role of TNF-alpha. FEMS Immunol. Med. Microbiol. 2002; 32: 133-40.
48. Waage A, Halstensen A, Espevik T, Brandtzaeg P. Compartmentalization of TNF and IL-6 in meningitis and septic shock. Med. Inflamm. 1993; 2: 23-5.
49. Melhus A, Ryan AF. Expression of cytokine genes during pneumococcal and nontypeable Haemophilus influenzae acute otitis media in the rat. Infect. Immun. 2000; 68: 4024-31.
50. Kyd JM, John A, Cripps AW, Murphy TF. Investigation of mucosal immunisation in pulmonary clearance of Moraxella (Branhamella) catarrhalis. Vaccine 2000; 18: 398-406.
51. Briles DE, Tart RC, Swiatlo E et al. Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin. Microbiol. Rev. 1998; 11: 645-57.
52. Kyd JM, Cripps AW. Towards a protein vaccine for nontypeable Haemophilus influenzae. Clin. Infect. Dis. 1999; 28: 238.
53. Webb DC, Cripps AW. Immunization with recombinant transferrin binding protein B enhances clearance of nontypeable Haemophilus influenzae from the rat lung. Infect. Immun. 1999; 67: 2138-44.
54. Verduin CM, Hol C, Fleer A, van Dijk H, van Belkum A. Moraxella catarrhalis: from Emerging to Established Pathogen. Clin. Microbiol. Rev. 2002; 15: 125-44.
55. Hsiao CB, Sethi S, Murphy TF. Outer membrane protein CD of Branhamella catarrhalis: sequence conservation in strains recovered from human respiratory tract. Microb. Pathogen. 1995; 16: 215-25.
56. Murphy TF, Brauer AL, Yuskiw N, McNamara ER, Kirkham C. Conservation of outer membrane protein E among strains of Moraxella catarrhalis. Infect. Immun. 2001; 69: 3576-80.